Table 2 Clinical application of CTCs in PC in recent years
From: Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation
Factors | Sensitivity | Specificity | AUC | Number of patients | Findings | Year of report | Ref | |
|---|---|---|---|---|---|---|---|---|
Diagnosis | CTCs + CA19-9 | 0.95 | 80 | the combination of CTCs and CA19-9 improves the diagnosis of pancreatic cancer | 2022 | [85] | ||
CTCs + Folate receptors + CA19-9 | 0.978 | 0.833 | 0.944 | 46 | folate receptors (+) CTCs, especially when combined with CA19‐9, have the potential as a biomarker for diagnosing pancreatic cancer | 2020 | [86] | |
CTCs + EVs GPC1 | 1 | 0.8 | 22 | combining CTCs and GPC1-positive-exosome detection displayed 100% sensitivity and 80% specificity in PDAC | 2019 | [87] | ||
CTCs | 0.75 | 0.964 | 0.867 | 72 | CTCs as a biomarker for diagnosis and staging in pancreatic cancer | 2016 | [88] | |
CTCs + CA19-9 | 0.67 | 0.8 | 52 | CA19-9, combined with CTCs analysis, may represent an efficient method for diagnosing pancreatic adenocarcinoma in patients with of solid pancreatic tumours | 2017 | [89] | ||
Prognosis | CTCs + KLF8 + vimentin | 40 | CTCs expressing Krüppel-like factor 8 and vimentin predict prognosis in pancreatic cancer | 2021 | [90] | |||
CTCs | 0.8 | 100 | CTCs correctly identified patients with occult metastatic disease preoperatively | 2018 | [91] | |||
Recurrence | CTCs + TIC markers | 60 | CTCs expressing markers of tumour-initiating cells predict survival and recurrence in PDAC | 2017 | [92] | |||
CTCs + vimentin + cytokeratin | 50 | CTCs expressing vimentin and cytokeratin predict the recurrence of PDAC | 2016 | [93] | ||||
CTCs | 36 | the presence or absence of CTCs in the blood of patients with PDAC could help predict the recurrence pattern after surgery | 2021 | [94] | ||||
Therapy | CTCs + vimentin + CA19-9 | 100 | significantly reduced CTCs counts were observed after chemotherapy in subjects that responded to treatment | 2019 | [95] | |||
CTCs | 0.82 | 0.85 | 0.871 | 200 | CTCs as a biomarker for 1-year recurrence for chemo-naive PDAC patients | 2018 | [96] |